Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma
NCT04414956 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1418
Last updated 2020-06-04
Summary
In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in patients with cirrhosis and compare the detection efficacy between tests.
Conditions
- Liver Cirrhosis
- Hepatocellular Carcinoma
- Surveillance
Interventions
- DIAGNOSTIC_TEST
-
AFP-L3
AFP-L3 will be tested using serum sample every 6 months.
- DIAGNOSTIC_TEST
-
AFP
AFP will be tested using serum sample every 6 months.
- DIAGNOSTIC_TEST
-
PIVKA-II
PIVKA-II will be tested using serum sample every 6 months.
- DIAGNOSTIC_TEST
-
Sonography
Sonography will be tested by experts every 6 months.
- DIAGNOSTIC_TEST
-
CT
Contrast-enhanced CT will be tested annually.
Sponsors & Collaborators
-
Korea University Ansan Hospital
collaborator OTHER -
Soonchunhyang University Hospital
collaborator OTHER -
Korea University Guro Hospital
collaborator OTHER -
The Catholic University of Korea
collaborator OTHER -
Samsung Medical Center
collaborator OTHER -
Asan Medical Center
collaborator OTHER -
Korea University Anam Hospital
collaborator OTHER -
Keimyung University Dongsan Medical Center
collaborator OTHER -
Severance Hospital
collaborator OTHER -
Hanyang University
collaborator OTHER -
Konkuk University Hospital
collaborator OTHER -
Seoul National University Hospital
collaborator OTHER -
Inje University
collaborator OTHER -
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
collaborator OTHER -
Korea University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- SCREENING
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-01
- Primary Completion
- 2023-06-30
- Completion
- 2026-02-28
Countries
- South Korea
Study Locations
More Related Trials
-
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Diagnostic Value of AFP-L3 and PIVKA-II in HCC
NCT03460080 ·Status: UNKNOWN
-
Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
NCT01446666 ·Status: COMPLETED
-
Searching for the Liver Cancer-Related Biomarkers
NCT00154544 ·Status: UNKNOWN
-
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
NCT06134973 ·Status: RECRUITING
-
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
NCT00373347 ·Status: COMPLETED
-
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
NCT00629421 ·Status: COMPLETED
-
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
NCT06537193 ·Status: RECRUITING ·Phase: NA
-
Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance
NCT02854241 ·Status: UNKNOWN ·Phase: NA
-
Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma
NCT04847726 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
NCT01492127 ·Status: UNKNOWN ·Phase: NA
-
Non-contrast Abbreviated MRI for Secondary Surveillance of HCC
NCT05690451 ·Status: COMPLETED
-
Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)
NCT01447667 ·Status: COMPLETED ·Phase: NA
-
Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC
NCT04212273 ·Status: UNKNOWN ·Phase: NA
-
AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver
NCT01361061 ·Status: COMPLETED
-
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
NCT06060769 ·Status: RECRUITING
-
Retrospective Analysis of De-identified Deceased HCC Patients
NCT04477720 ·Status: COMPLETED
-
Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease
NCT01350167 ·Status: UNKNOWN ·Phase: NA
-
HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC
NCT03020342 ·Status: UNKNOWN
-
Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC
NCT04722120 ·Status: COMPLETED ·Phase: NA
-
Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.
NCT02826005 ·Status: UNKNOWN ·Phase: NA
-
B-mode Ultrasound Imaging in Detecting Early Liver Cancer
NCT02774161 ·Status: COMPLETED ·Phase: NA
-
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
NCT07147335 ·Status: RECRUITING
-
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
NCT04455932 ·Status: RECRUITING ·Phase: NA
-
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark
NCT00902902 ·Status: UNKNOWN